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Abstract
The transcription factor p73, a member of the p53 family, mediates cell-cycle arrest and apoptosis
in response to DNA damage-induced cellular stress, acting thus as a proapoptotic gene. Similar to
p53, p73 activity is regulated by post-translational modification, including phosphorylation,
acetylation and ubiquitylation. In C. elegans, the F-box protein FSN-1 controls germline apoptosis
by regulating CEP-1, the single ancestral p53 family member. Here we report that FBXO45, the
human ortholog of FSN-1, binds specifically to p73 triggering its proteasome-dependent
degradation. Importantly, SCFFBXO45 ubiquitylates p73 both in vivo and in vitro. Moreover,
siRNA-mediated depletion of FBXO45 stabilizes p73 and concomitantly induces cell death in a
p53-independent manner. All together, these results show that the orphan F-box protein FBXO45
regulates the stability of p73, highlighting a conserved pathway evolved from nematode to human
by which the p53 members are regulated by an SCF-dependent mechanism.
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Introduction
The covalent attachment of an ubiquitin chain to a target protein occurs through sequential
steps catalysed by three different enzymes: the ubiquitin-activating enzyme (E1), the
ubiquitin-conjugating enzyme (E2) and the ubiquitin ligase (E3) enzymes (Hershko, 2005).
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A large number of E3s have been identified so far, reflecting their crucial role to recognize
and physically bind to specific substrates (Hershko, 2005; Petroski and Deshaies, 2005;
Bernassola et al., 2008). The SCF complexes are the most characterized class of RING-
finger-type E3s (Cardozo and Pagano, 2004). They are composed of four subunits: Skp1,
Cul1, RBX1 (also known as ROC1) and a F-box protein. Cul1 is a scaffold protein that
interacts at the amino terminus with the adaptor subunit Skp1 and at the carboxyl terminus
with the RING-finger protein ROC1 that accounts for the binding to specific E2-conjugating
enzymes. In humans, sixty-nine SCF ligases have been identified to date, each characterized
by a different F-box protein subunit that provides specificity by recognizing different
substrates (Cenciarelli et al., 1999; Winston et al., 1999). Notably, only nine out of sixty-
nine human SCF ubiquitin ligases have well-established substrates, many of which are
involved in cell-cycle control, cell growth, apoptosis, DNA damage response and
tumorigenesis (Dorrello et al., 2006; Peschiaroli et al., 2006; Frescas and Pagano, 2008).
p73 is a structural and functional homolog of the tumor suppressing transcription factor p53
(Kaghad et al., 1997; Tomasini et al., 2008a). Similarly to p53, p73 has three different
domains: an N-terminal transactivation domain, a central DNA-binding domain and C-
terminal oligomerization domain (Levrero et al., 1999; Melino, 2003). However, p73
displays a higher level of structural complexity than p53, existing as several distinct protein
isoforms resulting from alternative splicing, alternative promoter usage or alternative
initiation of translation (De Laurenzi et al., 1998, 1999). In particular, the usage of the
alternative internal promoter gives rise to N-terminally truncated proteins (ΔN isoforms),
which lack the transactivation domain and, as a result, act as dominant negative inhibitors of
p53 and TAp73 functions (Grob et al., 2001).
On the basis of their structural homology, p73 and p53 should exert similar biological
outcome. In fact, ectopic TAp73 is able to bind p53 responsive element and to mediate cell-
cycle arrest and apoptosis in response to DNA damage-induced cellular stress (Bergamaschi
et al., 2003; Melino et al., 2004; Ramadan et al., 2005), acting thus as a proapoptotic factor.
On the contrary, ΔNp73 proteins promote cell survival and exhibit oncogenic properties.
Specifically, ΔNp73 has been shown to induce immortalization of primary cells, cooperate
with oncogenic Ras in cellular transformation and promote tumor growth in nude mice
(Petrenko et al., 2003).
Although the role of p73 during tumorigenesis in vivo has been controversial (Yang et al.,
2000; Melino et al., 2002; Flores et al., 2005; Perez-Losada et al., 2005), probably due to
the pro- and antiapoptotic function elicited by the TAp73 and ΔNp73 isoforms, respectively,
a recent paper has established a tumor suppressor function for the TAp73 (Tomasini et al.,
2008a). Indeed, TAp73−/− mice are tumor prone, sensitive to carcinogens and exhibit
genomic instability (Tomasini et al., 2008a, b).
TAp73 protein levels are induced by a wide variety of chemotherapeutic agents in a manner
distinct from p53 (Agami et al., 1999; Gong et al., 1999; Yuan et al., 1999), while ΔNp73 is
rapidly degraded in response to cellular stress (Maisse et al., 2004). As a result of the
opposite activities exerted by TAp73 and ΔNp73 proteins, the balance between cell death
and survival, particularly in cells harboring p53 mutations will crucially depend on the
relative proportions of the two isoforms.
Similar to p53, p73 expression is maintained at low levels in mammalian cells, and its
cellular induction and activation is controlled at the post-translational level, mainly by
ubiquitin-dependent mechanism (Bernassola et al., 2004; Maisse et al., 2004; Watson and
Irwin, 2006). Different E3s have been shown to regulate the stability of p73. Our group has
previously demonstrated that the HECT-type E3 Itch controls the proteasome-dependent
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degradation of p73, maintaining its protein levels low in unstressed conditions (Rossi et al.,
2005). Interestingly, in C. elegans the F-box protein FSN-1 controls the activity of CEP-1,
the single ancestral p53 family member, thus regulating germline apoptosis (Gao et al.,
2008). This prompted us to investigate the possibility that the human ortholog of FSN-1, the
F-box protein FBXO45, also played a role in regulating p73. Indeed, here we report data
demonstrating that FBXO45 specifically binds to and promotes p73 ubiquitylation, thus
triggering its proteasomal degradation. Importantly, siRNA-mediated depletion of FBXO45
induces stabilization of p73 and enhances the cell death induced by chemotherapic agents.
Moreover, we show that, similarly to Itch, FBXO45 is downregulated in response to DNA
damage and its decrease is essential to allow p73 levels to rise.
Results
Cul1-dependent regulation of p73 protein level
To investigate the putative role of a Cullin-based E3 ligase in controlling p73 protein levels,
we took advantage of a CHO-derived ts41 cell line harboring a temperature-sensitive
mutation in the APP-BP1 gene encoding the Nedd8 E1-activating enzyme (Handeli and
Weintraub, 1992). Nedd8 is an ubiquitin-like protein, whose covalent attachment to cullins
is required for the activity of Cullin-based E3 ligases (Morimoto et al., 2003; Saha and
Deshaies, 2008). We transfected HA-tagged p73 (HA-TAp73) into ts41 cells and analysed
by immunoblot (IB) p73 levels either at permissive (34 °C) or not permissive (40 °C)
temperature. At 40 °C the neddylation pathway is inhibited, as shown by the lack of the
nedd8 modification of Cul2 (Figure 1a). In concomitance with the inactivation of the
Nedd8-conjugation pathway, we observed an increase in p73 protein levels (Figure 1a). This
effect is specific for p73 as the other members of the p53 family, p63 and p53, are not
regulated in the same manner (Figure 1b).
In humans there are five different cullin proteins, all of them requiring the Nedd8
modification to exert their function (Hori et al., 1999; Osaka et al., 2000; Parry and Estelle,
2004). We investigated which cullin proteins account for the increase of the p73 level
observed in ts41 cells. We co-transfected HA-TAp73 with different dominant negative
mutants of cullins and then analysed p73 levels by IB. Expression of Cul1 dominant
negative mutant, but not Cul2, Cul3, Cul4 and Cul5 dominant negative mutants, increased
p73 levels (Figure 1c) to an extent similar to that observed in the ts41 cell line at not
permissive temperature, suggesting that a Cul1-associated activity is required for p73
protein stability.
Cul1 is the scaffold protein of the SCF complexes and many substrates of this class of E3s
were found to be associated with Cul1 (Donzelli et al., 2002; Peschiaroli et al., 2006).
Therefore, we tested whether a complex between TAp73 and Cul1 can be observed in vivo.
We performed an in vivo co-immunoprecipitation experiments and found that endogenous
Cul1 indeed binds Flag-tagged TAp73 (Figure 1d). All these results imply a role for an SCF
complex in the regulation of p73 protein level.
The F-box protein FBXO45 binds specifically to p73
In C. elegans the F-box protein FSN-1 controls germline apoptosis by regulating the p53
ortholog, CEP-1 (Gao et al., 2008). Among the 520 predicted F-box proteins of C.elegans,
FSN-1 is among the few to be conserved through evolution and its human ortholog is
FBXO45 (Kipreos and Pagano, 2000; Thomas, 2006). This has prompted us to investigate
whether FBXO45 could interact with p73. To this aim, we screened different human F-box
proteins for their ability to bind to p73. Flag-tagged versions of F-box proteins were co-
transfected with HA-tagged p73 into HEK293T cells (adding the proteasome inhibitor
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MG132 for 6h before harvesting the cells) and then immunoprecipitated to evaluate their
interaction with p73. We found that both wild-type FBXO45 and its F-box deleted mutant
(ΔF-FBXO45) interacted with p73 (Figure 2a), whereas related F-box proteins such as
FBXO11, FBXO4 and FBXO28 did not. Similarly, various additional F-box proteins (Skp2,
βTrcp, FBXW7 and FBXO9) did not co-immunoprecipitate p73 either (Figure 2a and data
not shown). Importantly, FBXO45 bound to both TAp73 and ΔNp73 isoforms, but not to
p53 (Figure 2b), indicating the specificity of the interaction between FBXO45 and p73. To
determine the region of p73 responsible for the binding to FBXO45, we generated a series of
p73 deletion mutants and tested their ability to bind Flag-tagged FBXO45 (Figure 2c). A N-
terminal p73 deletion mutant containing the oligomerization domain and the SAM domains
were able to co-immunoprecipitate with FBXO45, whereas the transactivation and the
DNA-binding domain localized in the N terminus did not. The p73 deletion mutant
containing only the oligomerization domain did not interact with FBXO45, suggesting that
the SAM domain of p73 is responsible for the binding to FBXO45 (Figure 2c).
At a structural level, human FBXO45 is characterized by an N-terminal F-box domain
(spanning from amminoacids 39–82) and a SPRY domain (spanning amino acids 152–284)
(Figure 2d). We investigated also which domain of FBXO45 is responsible for binding to
p73. The SPRY domain of FBXO45 was still able to interact with p73 (Figure 2d), while a
region containing just the F-box domain did not bind to TAp73, indicating that the SPRY
domain of FBXO45 mediates the interaction with p73.
FBXO45 induces the proteasome-dependent degradation of p73
It is well established that the F-box domain accounts for the binding to the adaptor protein
Skp1, whereas the other domains present in the F-box proteins are responsible for their
interaction with substrates (Cardozo and Pagano, 2004). As expected, wild-type FBXO45
was able to interact with endogenous Skp1, whereas the ΔF-FBXO45 mutant did not,
suggesting that the F-box domain of FBXO45 is functionally important to form an SCF
complex in vivo (see Supplementary Figure S1).
Since the SCF complexes generally regulate the proteasome-dependent degradation of target
proteins, we studied the effect of overexpressing FBXO45 on p73 levels. HA-TAp73 was
co-transfected into neuroblasoma SH-SY5Y cells in the presence of either wild-type Flag-
tagged FBXO45 or ΔF-FBXO45. As shown in Figure 3a, TAp73 protein levels were
efficiently downregulated by the coexpression of wild-type FBXO45, both under unstressed
conditions and after DNA damage. FBXO45 expression was also able to negatively
modulate the expression of ΔNp73 (Figure 3b). Importantly, the ΔF-FBXO45 mutant, which
was still able to bind p73 (see Figures 2a and d), was not capable to negatively modulate
both TAp73 and ΔNp73 levels (Figures 3a and b and Supplementary Figure S2), confirming
the requirement of an intact SCFFBXO45 complex for regulating p73 protein levels. To assess
whether the FBXO45-mediated dowregulation of p73 is due to proteasome-dependent
degradation, we treated SH-SY5Y cells expressing both wild-type FBXO45 and p73 with
the proteasome inhibitor MG132. As shown in Figure 3c, exposure to MG132 totally
rescued FBXO45-dependent downregulation of p73, demonstrating that FBXO45 controls
the proteasome-dependent degradation of p73 in vivo.
SCFFBXO45 ubiquitylates p73 in vivo and in vitro
Because a major function of F-box proteins involves the ubiquitylation of their target
substrates, we sought to determine whether FBXO45 ubiquitylates p73 in mammal cells. To
this aim, we transfected the constructs expressing myc-tagged FBXO45, Flag-tagged TAp73
and HA-tagged ubiquitin into SH-SY5Y cells. We then performed immunoprecipitation with
an anti-FLAG antibody-conjugated M2 beads under denaturing conditions to eliminate any
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p73-associated proteins through non-covalent bonds. Ubiquitin-conjugated p73 species were
detected by IB with an anti-Flag antibody. As shown in Figure 4a, the expression of
FBXO45 enhanced the ubiquitylation of p73 as compared with the control vector (compare
lane 2 with lane 4). We also reconstituted the ubiquitylation of p73 in vitro by using a
semipurified system. Flag-tagged wild-type FBXO45 or its mutant ΔF-FBXO45 were
transfected into HEK293T cells and then purified by immunoprecipitation with anti-Flag
antibody. After extensive washes, the beads containing the SCFFBXO45 or SCFΔF–FBXO45
complexes were mixed to an in vitro ubiquitylation reaction containing immunopurified
TAp73. FBXO45, but not its F-box deleted mutant ΔF-FBXO45, was able to promote the
ubiquitylation of purified p73 (Figure 4b). A different F-box protein, FBXO11, was unable
to trigger the ubiquitylation of p73, confirming the specificity of FBXO45. All these results
indicate that FBXO45 promotes p73 ubiquitylation both in vivo and in vitro.
Silencing of FBXO45 induces p73 stabilization and cell death in the absence of functional
p53
p73 activity controls different processes, including the apoptotic response to DNA damage
and neuronal differentiation (Yuan et al., 1999; De Laurenzi et al., 2000). To test whether
the DNA damage response regulates FBXO45 expression, we performed an RT– PCR
analysis in cells treated with doxorubicin, a DNA damage-inducing agent. Figure 5a showed
that FBXO45 expression was downregulated after DNA damage both in SH-5YSY cells and
BT-20 breast cancer cells. On the contrary, we did not observe any significant variation of
FBXO45 mRNA levels in SH-5YSY cells treated with retinoic acid to induce neuronal
differentiation (data not shown). The results presented above prompted us to test whether the
depletion of FBXO45 could increase p73 protein levels and thus potentiate apoptotic
response to a DNA-damage agent. To this end, we used the siRNA technique to reduce the
expression of FBXO45 in the BT-20 cell line, which harbors a mutation in the p53 locus,
thus, avoiding p53-dependent apoptosis (Chopin et al., 2002). We first tested two different
siRNA oligos for their ability to downregulate FBXO45. Both oligos were able to decrease
FBXO45 expression at the mRNA level and induced a concomitante accumulation of p73
(Figure 5b). Importantly, FBXO45 depletion did not affect the mRNA level of p73 (Figure
5b), indicating that it specifically controls p73 protein stability.
To determine whether FBXO45 downregulation could sensitize cells to apoptosis, we
treated the FBXO45-depleted cells with doxorubicin and we measured the apoptotic index
after DNA damage. In concomitance with the upregulation of p73, FBXO45-depleted cells
showed a marked increase in the apoptotic index (Figure 5c), indicating thus that FBXO45
could regulate cell death in the absence of functional p53.
Discussion
The F-box proteins recruit specific substrates to the E3 ligase SCF complex, thus targeting
them to proteasome-dependent degradation (Cardozo and Pagano, 2004). Despite the large
number of F-box proteins, only nine human SCF ubiquitin ligases have well-established
substrates, many of which are involved in cell-cycle control, apoptosis and DNA damage
response (Peschiaroli et al., 2006; Frescas and Pagano, 2008).
p73, a member of the p53 family, is a transcription factor controlling different biological
processes, including cell death, tumorigenesis and neuronal differentiation (Melino, 2003).
Similar to p53, p73 activity and protein levels are strictly controlled by post-translational
modifications, including ubiquitylation. Knowledge on the mechanisms regulating p73
levels in basal conditions as well as in response to stress is essential to design new therapies
that require p73 induction. Our group has previously shown that the HECT E3 ubiquitin
ligase Itch is capable to polyubiquitylate p73 and induce its degradation in a proteasome-
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dependent manner. In unstressed cells, Itch targets both TAp73 and δNp73 isoforms for
protein ubiquitylation, thereby keeping their expression levels low under normal conditions
(Rossi et al., 2005). In response to DNA-damaging agents, Itch is downregulated allowing
TAp73 levels to rise. Clearly, this is not the only mechanism regulating p73 stability and
here we report indeed the identification of the F-box protein FBXO45 as a new player in the
regulation of p73. We show that FBXO45 is able to bind to p73 promoting its ubiquitylation
and its proteasome-dependent degradation. Moreover, we found that FBXO45, similar to
Itch, is downregulated in response to DNA damage, allowing thus p73 levels to increase in
response to stress.
p73 gene encodes for two major proteins, the proapoptotic TA and the antiapoptotic δN
isoform (Levrero et al., 1999). Our data indicates that exogenously expressed FBXO45 is
able to bind to both TA and δN isoforms with similar affinities, suggesting that FBXO45,
similar to Itch, is not able to discriminate between these two isoforms. In agreement with
this, FBXO45 overexpression promotes the proteasome-dependent degradation of both TA
and δN isoforms. We cannot rule out the possibility that the endogenous expression levels of
the two isoforms and/or different stimuli can determine a preferential binding to FBXO45 of
one isoform with respect to the other, inducing thus different biological outcomes. However,
our data once again leaves us with the idea that an unidentified degradation pathway,
activated in response to DNA damage, specific for δNp73, must exist.
The importance of SCF-dependent regulation of p73 is also highlighted by the fact that this
mechanism is conserved through evolution. As a matter of fact a recent report has described
that the worm ortholog of FBXO45, the F-box protein FSN-1, is implicated in germline
apoptosis through the regulation of the apoptotic activity of CEP-1 (Gao et al., 2008).
Similar to its vertebrate relatives, the C.elegans p53-like gene CEP-1 is the key regulator of
the cell death after genotoxic stress (Derry et al., 2001; Schumacher et al., 2001). CEP-1
expression is induced after DNA damage and its activation controls germline apoptosis. Gao
et al. reported that CEP-1 activity is strictly regulated by the SCF complex SCFFSN–1.
FSN-1-null mutants exhibit higher induction of CEP-1 levels after genotoxic stress and
concomitantly a higher apoptotic index. Structurally the DNA-binding domain of CEP-1 is
similar to the one of human p53, but its C terminus contains a SAM domain that resembles
the C terminus of vertebrate p63 and p73 (Ou et al., 2007), suggesting its similarity with the
p63/p73 ancestor. Although we cannot completely rule out a possible involvement of
FBXO45 in the regulation of p63 and p53 activity, our data indicate that FBXO45 controls
specifically the protein degradation of p73. In fact, FBXO45 is able to interact with p73, but
not with p53. Moreover, we found that the protein level of p53 and p63 are not affected by
the inhibition of the neddylation pathway, suggesting that the activity of the SCF complex is
not implicated in the regulation of p53/p63 stability. Accordingly, it has previously
described that the neddylation pathway regulates the transcriptional activity of p53, but not
its stability (Abida et al., 2007).
In C. elegans, the genetic depletion of FSN-1 or Cul1 induces germline apoptosis through
the increase of CEP-1 protein levels (Gao et al., 2008). In line with these data, we showed
that the siRNA-mediated depletion of FBXO45 increases p73 protein levels and sensitizes
cells to DNA damage inducing apoptosis. Moreover, we found that the expression of the
dominant negative mutants of Cul1, but not of Cul2, Cul3, Cul4 and Cul5 dominant negative
mutants, induces p73 protein stabilization. From all these data, it seems that an SCF-
dependent regulation of the p53 family members is a mechanism that has been conserved
through evolution, reinforcing the important physiological role played by this pathway.
The F-box proteins generally recruit substrates in a phosphorylation-dependent manner
(Skowyra et al., 1997). Different kinases have been reported to be able to phosphorylate
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p73. In response to DNA-damaging agents, the non-receptor tyrosine kinase c-Abl phos-
phorylates p73 at Tyr99 leading to an increase in p73 stability (Gong et al., 1999).
Moreover, p73 was found to interact with cyclin-dependent kinases such as cyclin A/cdk2
and cyclin E/cdk2, and threonine 86 of p73 could be phosphorylated by these kinases in
vitro (Gaiddon et al., 2003). More recently, the cell cycle regulated kinase Plk1 has been
shown to interact with p73 and to induce its phosphorylation at threonine 27 (Koida et al.,
2008; Soond et al., 2008). Interestingly, the Plk1-dependent phosphorylation of p73 seems
to negatively regulate p73 protein stability (Soond et al., 2008). However, our unpublished
results suggest that Plk1 activity is not involved in FBXO45-dependent degradation of p73.
It will be important in the future to determine whether the FBXO45-dependent degradation
of p73 is dependent on some of the above-mentioned phosphorylation events or on another
kinase activity.
In conclusion, we showed that FBXO45 binds to and stimulates the proteasome-dependent
degradation of p73. As FBXO45 depletion sensitizes cell to apoptosis in a p53-null
background, we elucidate a potential new mean that could be used to develop new strategies
aimed to potentiate the apoptotic response of cancer cells after chemotherapy. Importantly,
we undercovered a conserved mechanism by which the p53 family members are regulated in
response to genotoxic stress.
Materials and methods
Cell culture, transfection conditions and reagents
Human embryonic kidney HEK293T, human epithelial carcinoma HeLa, human
neuroblastoma SH-5YSY and human breast cancer cell line BT-20 were maintained at 37°C
and 5% CO2 in Dulbecco’s modified Eagle’s medium supplemented with 100 µg/ml
penicillin, 100 µg/ml streptomycin and 10% fetal bovine serum. Chinese hamster ovary
Ts41 cell line was maintained at 34°C, and then shifted to non-permissive temperature (40
°C) to inhibit the neddylation pathway. Transfections were performed using the calcium
phosphate method for HEK293T, Effectene (Qiagen, Hilden, Germany) for HeLa and BT-20
and Lipofectamine LTX (Invitrogen, Grand Island, NY, USA) for SH-5YSY, according to
the manufacturer’s instructions. Cells have been treated for 6 h with 10 M proteasome
inhibitor MG132 (Calbiochem, San Diego, CA, USA) and/or with 2 M doxorubicin
hydrochloride (Sigma, Taufkirchen, Germany) when appropriate. The following pcDNA3.1
expression constructs for the F-box proteins were kindly provided by Michele Pagano (NYU
School of Medicine): myc-FBXO45, Flag-βTrCP, Flag-FBXO4, Flag-FBXO28 and Flag-
Skp2. The pcDNA3.1 expression vector for wild-type Flag-tagged FBXO45 has been
obtained by subcloning the FBXO45 cDNA into the pcDNA3.1 Flag-B vector. The ΔF-
FBXO45 deletion mutant has been generated by PCR using the following primers: 5′-
CGGGATCCATGGATTACAAG GAGGATGACGACG
ATAAGTGCGCCCGCAGCCTGG CAGAAGAG-3′ and 5′-
CCGCTCGAGTCATCCGTCCAAA GGTTTTCCAAGGTAAACC-3′. The ΔSPRY
deletion mutant was generated by digestion with Apa1 restriction enzyme using pcDNA3.1
Flag wt-FBXO45 as a template followed by ligation.
Immunoblot analysis, immunoprecipitation and antibodies
Immunoblot analysis has been performed using whole-cell extracts obtained by lysing the
cell pellet with Triton Buffer (50 mM Tris-Hcl, pH 7.5, 250 mM NaCl, 50 mM NaF, 1mM
EDTA 1 pH 8, 0,1% Triton), supplemented with proteases and phosphatases inhibitors, and
with 20 M N-ethylmaleimide (Sigma) when required. Proteins were subsequently separated
by SDS–polyacrylamide gel electrophoresis, blotted onto poly-vinylidene difluoride
membranes (Millipore, Billerica, MA, USA) and then blocked with phosphate-buffered
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saline and 0.1%Tween-20 containing 5% non-fat dry milk for 1 h at room temperature. The
incubation with primary antibodies was performed for 2 h at room temperature, followed by
appropriate horseradish peroxidase-conjugated secondary antibody for 1 h at room
temperature. After extensive washing, detection was performed with the ECL Western Blot
Chemiluminescence Reagent (Perkin Elmer, Waltham, MA, USA).
Immunoprecipitation has been performed by preclearing 1 mg of whole cell lysates with
protein A/G-Sepharose beads (GE Healthcare, Chalfont St. Giles, UK) for 3 h and then by
incubating overnight at 4°C with the appropriate amount of antibody per sample. Finally, the
immunocomplexes have been absorbed on protein A/G-Sepharose beads, washed six times
in Triton lysis buffer and used for in vitro ubiquitylation assay or eluted by boiling in SDS
loading buffer.
We used the following antibodies: mouse monoclonal anti-HA (ascites, Covance, Princeton,
NJ, USA), rabbit polyclonal anti-GFP (Roche, Indianapolis, IN, USA), rabbit polyclonal
anti-Cul2 (Zymed, Invitrogen), mouse monoclonal anti-β-actin (Sigma), mouse monoclonal
anti-Myc (Cell Signaling, Beverly, MA, USA), rabbit polyclonal anti-Flag (Sigma), mouse
monoclonal anti-Cul1 (Zymed), mouse monoclonal anti-p53 (DO-1, Santa Cruz, Santa Cruz,
CA, USA), mouse monoclonal anti-p73 (Imgenex, San Diego, CA, USA) and rabbit
polyclonal anti-p73 (Rossi et al., 2005).
Ubiquitylation assays
In vivo ubiquitylation assay was performed using SH-5YSY neuroblastoma cells, transiently
transfected with cDNAs encoding human Flag-tagged p73 (Flag-p73), myc-tagged FBXO45
(myc-FBXO45) and HA-tagged ubiquitin (HA-Ub) and treated with MG132 before
collecting. Cells were lysed in denaturing condition (0.15 mM NaCl/0.05 mM Tris • HCl, pH
7.2/1% Triton X-100/1% sodium deoxycholate/0.1% SDS) in the presence of 20 M N-
ethylmaleimide (Sigma), and Flag-p73 has been immunoprecipited as described above.
Polyubiquitylated p73 species were detected using anti-Flag antibody.
In vitro ubiquitylation assay was carried out using SCFFBXO45 complexes immunopurified
from HEK393T cells transfected with His-tagged Skip and Flag-tagged FBXO45 using the
method described above. The beads containing the SCFFBXO45 immunocomplexes were
washed twice with equilibration buffer (25 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM EDTA,
0.01% Triton and 10% glycerol) and then added to the following reaction: 30 ng of E1, 0.5g
of UbcH3, 0.5g of UbcH5, 5g of ubiquitin in the ubiquitylation buffer (2.5 mM Tris-HCl, 0.7
mM dithiothreitol, 4 mM ATP, 10 mM MgCl2, 0.1 mM ubiquitin aldehyde) in a final volume of
30 l. The HA-tagged p73 (HA-p73) protein used as substrate for the reaction has been
purified by immunoprecipitation with the hemagglutinin-antibody and then eluted with the
hemagglutinin peptide (1 mg/ml). The assays have been carried out for 90 min at 30 °C, then
the immunocomplexes were eluted by boiling in SDS loading buffer and loaded in SDS–
polyacrylamide gel electrophoresis.
siRNA-mediated silencing of FBXO45 and detection of apoptosis
SH-5YSY and BT-20 cells were seeded at a density of 1.4 × 105 cells per well in a six-well
plate and transfected with oligos twice (at 24 and 48 h after plating) using Oligofectamine
(Invitrogen) according to the manufacturer’s instructions. Two different 21-nucleotide RNA
oligos were used, targeting the following FBXO45 cDNA sequences: 5′-CAGACGTTA
CTATTATCCCTA-3′ and 5′-CTGGTGGACAATAATCTA CTA-3′. A 21-nt siRNA duplex
corresponding to a non-relevant gene (scramble) was used as control. Cells were collected
after 48 h and lysates were subjected to western blot. To evaluate the efficiency of silencing,
we measured the FBXO45 mRNA level by reverse transcription–PCR using total RNA
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extracted by FBXO45-depleted cells. Alternatively, after siRNA transfection, we transfected
the siRNA expressing cells with vector encoding Flag-tagged FBXO45. After 24 h, cells
were lysed and total cell extracts were analysed by IB using the Flag antibody.
Quantification of sub-G1 population was performed by FACS analysis of propidium iodide-
staining nuclei (Nicoletti et al., 1991), carried out in an FACScan flow cytometer (Becton
Dickinson, Heidelberg, Germany) using the CELL-Quest software system.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Cul1-associated activity regulates p73 protein levels. (a), ts41 cells were co-transfected at
permissive temperature (34 °C) with HA-tagged TAp73 (HA-TAp73) and green fluorescent
protein (GFP). Twenty-four hours after transfection, cells were either left at the permissive
temperature or shifted to non-permissive temperature (40 °C) for 24 h. Cell lysates were
immunoblotted with anti-HA and anti-actin antibodies. Blots were re-probed with antibodies
against Cul-2 and GFP, as a control of impaired neddylation pathway and transfection
efficiency, respectively. (b), ts41 cells were co-transfected with either HA-TAp63, HA-
ΔNp63, or HA-p53 together with GFP. Cells were treated as in A, and cell lysates were
analysed by immunoblotting (IB) with antibodies against HA and GFP. (c), HeLa cells were
transfected with a plasmid coding HA-TAp73 in the absence or in the presence of the Flag-
tagged ΔN252Cul1 mutant, and different myc-tagged neddylation site mutants of Cul2,
Cul3, Cul4 and Cul5. Cellular extracts were analysed by IB using anti-HA, anti-Flag and
anti-myc antibodies. Blots were re-probed with anti-actin antibody as loading control. (d)
HEK293T cells were transfected with Flag-tagged TAp73 and cell extracts were
immunoprecipitated with anti-Flag antibody and analysed with anti-Flag and anti-Cul1
antibodies.
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Figure 2.
FBXO45 interacts specifically with p73, both TA and ΔN isoforms. (a), HEK293T cells
were co-transfected with the indicated Flag tagged F-box protein constructs (FBPs) and HA-
TAp73. During the last 6 h before harvesting, cells were treated with 10 µM of the
proteasome inhibitor MG132. Exogenous proteins were immunoprecipitated (IP) from cell
extracts with anti-Flag resin and immunocomplexes were probed with antibodies to the
indicated proteins. (EV=empty vector). (b), HEK293T cells were co-transfected with Flag-
tagged FBXO45 (Flag-FBXO45) together with either HA-TAp73, HA-ΔNp73 or HA-p53.
Cells extracts were IP using an anti-Flag antibody and immunocomplexes were probed with
antibodies to the indicated proteins. (c), HEK293T cells were co-transfected with the
indicated HA-tagged p73 deletion mutants and Flag-tagged FBXO45. During the last 6 h
before harvesting, cells were treated with 10 µM of the proteasome inhibitor MG132.
Exogenous proteins were IP from cell extracts with anti-Flag resin and immunocomplexes
were probed with antibodies to the indicated proteins. (EV, empty vector). (d), HEK293T
cells were co-transfected with the indicated Flag-tagged FBXO45 deletion mutants and HA-
tagged TAp73. During the last 6 h before harvesting, cells were treated with 10 µM of the
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proteasome inhibitor MG132. Exogenous proteins were IP from cell extracts with anti-Flag
resin and immunocomplexes were probed with antibodies to the indicated proteins.
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Figure 3.
FBXO45 promotes the proteasome-dependent degradation of p73. (a) SH-5YSY
neuroblastoma cells were co-transfected with HA-TAp73 together with either wild-type
Flag-FBXO45 or its mutant Flag-ΔF-FBXO45. Twenty-four hours after transfection, cells
were either left untreated or treated with doxorubicin (2 µM) for 16 h. Cellular extracts were
analysed by immunoblot (IB) using anti-HA and anti-Flag antibodies. Blots were re-probed
with anti-actin as loading control. (EV =empty vector). Asteriks represents a nonspecific
band. (b) SH-5YSY neuroblastoma cells were co-transfected with HA-ΔNp73 together with
either wild-type Flag-FBXO45 or its mutant Flag-ΔF-FBXO45. Cellular extracts were
analysed by IB using anti-HA and anti-Flag antibodies. Blots were re-probed with anti-actin
as loading control. (c) The experiment was performed as in (a) except that 10 µM of MG132
was added where indicated.
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Figure 4.
FBXO45 stimulates the ubiquitylation of p73 both in vivo and in vitro. (a) In vivo ubiquitin
ligation assay of TAp73 was conducted as described in Bloom and Pagano, 2005. Briefly,
SH-5YSY neuroblastoma cells were co-transfected with HA-TAp73 alone or in the presence
of the following proteins: empty vector (EV, lane 1), myc-tagged ubiquitin (lane 2), Flag-
FBXO45 (lane 3), Flag-FBXO45 and myc-ubiquitin (lane 4), Flag-Itch and myc-ubiquitin
(lane 5). After 24 h, cells were treated with 10 µM of proteasome inhibitor MG132 for 6 h
and then collected. Cell extracts were subjected to immunoprecipitation before denaturation
of protein samples. The immunoicomplexes were resolved in SDS–PAGE and analysed by
IB using the antibodies for the indicated proteins. (b) In vitro ubiquitin ligation assay of
immunopurified HA-TAp73 was conducted in the presence or absence of the following
proteins: immunopurified SCFFBXO45, immunopurified SCFFBXO11, immunopurified
SCFΔF–FBXO45. Samples were incubated at 30 °C for 90 min except that in lanes 1 and 3 that
were added to sample buffer. The bracket on the right side of the panel marks a ladder of
bands corresponding to polyubiquitylated p73.
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Figure 5.
FBXO45 expression is downregulated after DNA damage and its depletion by siRNA
sensitizes BT-20 breast cancer cell line to doxorubicin-induced cell death. (a) BT-20 breast
cancer cell line and SH-5YSY neuroblastoma cells were either left untreated or treated with
doxorubicin (2 µM) for 6 and 18 h. Total RNA was extracted from the cells and quantitative
RT–PCR (qRT–PCR) was performed using specific primer for FBXO45 and actin. (b)
BT-20 cells were transfected twice with siRNA molecules to a non-relevant mRNA (ctr) or
to two different oligos specific for FBXO45 (#1 and #3). Forty hours after transfection, total
RNA was isolated and qRT–PCR was performed as described in (a). Concomitantly cell
extracts were subjected to immunoblot using the indicated antibody. (c) BT-20 cells
transfected with siRNA as in (c), were either left untreated or treated with doxorubicin (2
µM) for 18 h. The percentage of sub-G1 cells was measured by FACS analysis. A
representative results is shown (mean ± s.d., n = 3).
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